Table 1 Characteristics of the SLE patients (n = 188) in relation to the presence of anti-HMGB1
Mean (range) or % | P valuea | |||
|---|---|---|---|---|
All patients n = 188 | Anti-HMGB1 positive n = 43 | Anti-HMGB1 negative n = 145 | ||
Age, years | 49.1 (18–88) | 44.9 (19–80) | 50.4 (18–88) | ns |
Females | 88.8 % | 88.4 % | 89.0 % | ns |
Disease duration, years | 10.9 (0–45) | 10.9 (0–39) | 10.9 (0–45) | ns |
Prednisolone dosage, mg/day | 5.1 (0–60) | 8.3 (0–60) | 4.2 (0–25) | ns |
SLICC/ACR damage index, score | 1.1 (0–8) | 1.2 (0–8) | 1.1 (0–8) | ns |
SLEDAI-2K, score | 2.5 (0–24) | 3.1 (0–24) | 2.3 (0–16) | ns |
PGA, score | 0.4 (0–4) | 0.6 (0–4) | 0.4 (0–3) | ns |
Patients meeting SLICC-12, n (%) | 183 (97.3) | 42 (97.7) | 141 (97.2) | ns |
Fulfilled ACR-82 criteria, n | 4.8 (3–9) | 5.0 (3–9) | 4.7 (3–8) | ns |
ACR-82 criteria, n (%) | ||||
1. Malar rash | 87 (46.3) | 20 (46.5) | 67 (46.2) | ns |
2. Discoid rash | 32 (17) | 7 (16.3) | 25 (17.2) | ns |
3. Photosensitivity | 103 (54.8) | 23 (53.5) | 80 (55.2) | ns |
4. Oral ulcers | 21 (11.2) | 6 (14) | 15 (10.3) | ns |
5. Arthritis | 144 (76.6) | 35 (81.4) | 109 (75.2) | ns |
6. Serositis | 72 (38.3) | 19 (44.2) | 53 (36.6) | ns |
7. Renal disorder | 43 (22.9) | 10 (23.3) | 33 (22.8) | ns |
8. Neurologic disorder | 11 (5.9) | 3 (7) | 8 (5.5) | ns |
9. Hematologic disorder | 106 (56.4) | 20 (46.5) | 86 (59.3) | ns |
10. Immunologic disorder | 92 (48.9) | 29 (67.4) | 63 (43.4) | 0.009 |
11. IF-ANA | 185 (98.4) | 42 (97.7) | 143 (98.6) | ns |